Amylase / lipase / protease (Creon, Pancreaze, Pertzye) — 2026 Medicare Part D coverage
amylase / lipase / protease — sold as Creon, Pancreaze, Pertzye, Viokace, Zenpep: 25 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover amylase / lipase / protease?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| CREON 12,000 UNT / 60,000 UNT / 38,000 UNT Delayed Release Oral Capsule brand · RxCUI 863841 | 324 (99%) | 3 | 1 | 0 | 0 |
| CREON 24,000 UNT / 120,000 UNT / 76,000 UNT Delayed Release Oral Capsule brand · RxCUI 863829 | 324 (99%) | 3 | 1 | 0 | 0 |
| CREON 3000 UNT / 15,000 UNT / 9500 UNT Delayed Release Oral Capsule brand · RxCUI 1113046 | 324 (99%) | 3 | 1 | 0 | 0 |
| CREON 36,000 UNT / 180,000 UNT / 114,000 UNT Delayed Release Oral Capsule brand · RxCUI 1373327 | 324 (99%) | 3 | 1 | 0 | 0 |
| CREON 6000 UNT / 30,000 UNT / 19,000 UNT Delayed Release Oral Capsule brand · RxCUI 863836 | 324 (99%) | 3 | 1 | 0 | 0 |
| Zenpep 10,000 UNT / 42,000 UNT / 32,000 UNT Delayed Release Oral Capsule brand · RxCUI 1595462 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 15,000 UNT / 63,000 UNT / 47,000 UNT Delayed Release Oral Capsule brand · RxCUI 1595473 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 20,000 UNT / 84,000 UNT / 63,000 UNT Delayed Release Oral Capsule brand · RxCUI 1595478 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 25,000 UNT / 105,000 UNT / 79,000 UNT Delayed Release Oral Capsule brand · RxCUI 1594673 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 3000 UNT / 14,000 UNT / 10,000 UNT Delayed Release Oral Capsule brand · RxCUI 1595292 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 40,000 UNT / 168,000 UNT / 126,000 UNT Delayed Release Oral Capsule brand · RxCUI 1995479 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 5000 UNT / 24,000 UNT / 17,000 UNT Delayed Release Oral Capsule brand · RxCUI 1595457 | 308 (94%) | 3 | 1 | 0 | 0 |
| Zenpep 60,000 UNT / 252,600 UNT / 189,600 UNT Delayed Release Oral Capsule brand · RxCUI 2669472 | 308 (94%) | 3 | 1 | 0 | 0 |
| PANCREAZE 10,500 UNT / 61,500 UNT / 35,500 UNT Delayed Release Oral Capsule brand · RxCUI 1806921 | 6 (2%) | 3 | 1 | 0 | 0 |
| PANCREAZE 16,800 UNT / 98,400 UNT / 56,800 UNT Delayed Release Oral Capsule brand · RxCUI 1806926 | 6 (2%) | 3 | 1 | 0 | 0 |
| PANCREAZE 21,000 UNT / 83,900 UNT / 54,700 UNT Delayed Release Oral Capsule brand · RxCUI 1806931 | 6 (2%) | 5 | 1 | 0 | 0 |
| PANCREAZE 4200 UNT / 24,600 UNT / 14,200 UNT Delayed Release Oral Capsule brand · RxCUI 1806966 | 6 (2%) | 3 | 1 | 0 | 0 |
| PANCREAZE 2,600 UNT / 15,200 UNT / 8,800 UNT Delayed Release Oral Capsule brand · RxCUI 2478455 | 5 (2%) | 3 | 1 | 0 | 0 |
| PANCREAZE 37,000 UNT / 149,900 UNT / 97,300 UNT Delayed Release Oral Capsule brand · RxCUI 2564412 | 5 (2%) | 3 | 1 | 0 | 0 |
| Viokace 10,440 UNT / 39,150 UNT / 39,150 UNT Oral Tablet brand · RxCUI 1247388 | 5 (2%) | 4 | 1 | 0 | 0 |
| Viokace 20,880 UNT / 78,300 UNT / 78,300 UNT Oral Tablet brand · RxCUI 1247381 | 5 (2%) | 5 | 1 | 0 | 0 |
| Pertzye 16,000 UNT / 60,500 UNT / 57,500 UNT Delayed Release Oral Capsule brand · RxCUI 1294128 | 2 (1%) | 5 | 1 | 0 | 0 |
| Pertzye 24,000 UNT / 90,750 UNT / 86,250 UNT / Delayed Release Oral Capsule brand · RxCUI 1929118 | 2 (1%) | 5 | 1 | 0 | 0 |
| Pertzye 4000 UNT / 15,125 UNT / 14,375 UNT Delayed Release Oral Capsule brand · RxCUI 1543006 | 2 (1%) | 4 | 1 | 0 | 0 |
| Pertzye 8000 UNT / 30,250 UNT / 28,750 UNT Delayed Release Oral Capsule brand · RxCUI 1294483 | 2 (1%) | 4 | 1 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.